May 08, 2022 – Umbralisib (Ukoniq) is a medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib (Ukoniq) inhibits multiple kinases. In biochemical and cell-based assays, Umbralisib inhibited PI3Kδ and casein kinase CK1ε. PI3Kδ is expressed in …
Umbralisib (Ukoniq): Drug recall because increased risk of patient death Read more »
April o5, 2016 – There have been indications that a heightened risk of heart failure may be associated with diabetes medications containing the pharmacologically active ingredients saxagliptin or alogliptin. In the US, this includes the FDA-approved drugs Saxagliptin (Onglyza), Saxagliptin/Metformin …
August 29, 2015 – This may after all not be so good news for Type 2-Diabetes patients on DPP-4 inhibitor medications. The American Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines containing the pharmacologically active …